solute carrier family 7 member 11  (Proteintech)

Journal: Biomedical Reports

Article Title: Peroxiredoxin 4 suppresses ferroptosis in esophageal squamous cell carcinoma by activating the phosphoinositide 3-kinase  signaling pathway

doi: 10.3892/br.2026.2133

Figure Lengend Snippet: PRDX4 is an important regulator of ferroptosis in ESCC cells. (A) Determination of MDA, LPO and GSH contents in KYSE270 cells after transfection with PRDX4 siRNA. (B) Western blot analysis of the protein levels of GPX4, SLC7A11 and PTGS2 in KYSE270 cells transfected with PRDX4 siRNA. (C) The relative protein levels of GPX4, SLC7A11 and PTGS2 in KYSE270 cells transfected with PRDX4 siRNA. (D) Determination of MDA, LPO and GSH contents in KYSE30 cells after transfection with pcDNA3.1-PRDX4. (E) Western blot analysis of the protein levels of GPX4, SLC7A11 and PTGS2 in KYSE30 cells transfected with pcDNA3.1-PRDX4. (F) The relative protein levels of GPX4, SLC7A11 and PTGS2 in KYSE30 cells transfected with pcDNA3.1-PRDX4. (G) Detection of the levels of MDA, LPO and GSH in the control group, PRDX4 siRNA group and PRDX4 siRNA plus Fer-1 group in KYSE270 cells. (H) Western blot analysis of the protein expression levels of GPX4, SLC7A11 and PTGS2 in the control group, PRDX4 siRNA group and PRDX4 siRNA plus Fer-1 group in KYSE270 cells. (I) The relative protein levels of GPX4, SLC7A11 and PTGS2 in the control group, PRDX4 siRNA group and PRDX4 siRNA plus Fer-1 group in KYSE270 cells. (J) Detection of the levels of MDA, LPO and GSH in the pcDNA3.1 group, pcDNA3.1-PRDX4 group and pcDNA3.1-PRDX4 plus erastin group in KYSE30 cells. (K) Western blot analysis of the protein expression levels of GPX4, SLC7A11 and PTGS2 in the pcDNA3.1 group, pcDNA3.1-PRDX4 group and pcDNA3.1-PRDX4 plus erastin group in KYSE30 cells. (L) The relative protein levels of GPX4, SLC7A11 and PTGS2 in the pcDNA3.1 group, pcDNA3.1-PRDX4 group and pcDNA3.1-PRDX4 plus erastin group in KYSE30 cells. ** P<0.01, *** P<0.001 and **** P<0.0001, indicate statistical significance. PRDX4, peroxiredoxin 4; ESCC, esophageal squamous cell carcinoma; siRNA, small interfering RNA; MDA, malondialdehyde; LPO, lipid peroxidation; GSH, glutathione; GPX4, glutathione peroxidase 4; SLC7A11, solute carrier family 7 member 11; PTGS2, prostaglandin-endoperoxide synthase 2; Fer-1, ferrostatin-1; ns, not significant.

Article Snippet: The primary antibodies were as follows: Anti-PRDX4 (1:2,000 dilution; cat. no. 10703-1-AP), anti-E-cadherin (1:20,000 dilution; cat. no. 20874-1-AP), anti-N-cadherin (1:2,000 dilution; cat. no. 22018-1-AP), anti-Vimentin (1:20,000 dilution; cat. no. 10366-1-AP), and anti-GPX4 (1:1,000 dilution; cat. no. 30388-1-AP; all from Proteintech Group, Inc.), anti-solute carrier family 7 member 11 (SLC7A11; 1:1,000 dilution; cat. no. DF12509; Affinity Biosciences, Ltd.), anti-prostaglandin-endoperoxide synthase 2 (PTGS2; 1:1,000 dilution; cat. no. 27308-1-AP; Proteintech Group, Inc.), anti-p-PI3K (1:1,000 dilution; cat. no. AP0427; ABclonal Biotech Co., Ltd.), anti-PI3K (1:1,000 dilution; cat. no. A19742; ABclonal Biotech Co., Ltd.), anti-p-AKT (1:2,000 dilution; cat. no. 28731-1-AP; Proteintech Group, Inc.), anti-AKT (1:2,000 dilution; cat. no. 10176-2-AP; Proteintech Group, Inc.) and anti-β-actin (1:2,000 dilution; cat. no. 20536-1-AP; Proteintech Group, Inc.).

Techniques: Transfection, Western Blot, Control, Expressing, Small Interfering RNA